- Among people with type 2 diabetes (T2D) and coronary artery disease (CAD), empagliflozin is associated with a significant reduction in left ventricular mass indexed (LVMi) to body surface area (BSA) after 6 months.
Why this matters
- Underlying mechanisms of empagliflozin’s cardiovascular benefits seen in the EMPA-REG OUTCOME study are unknown.
- Study of 97 adults with T2D and CAD were randomly allocated to 10 mg/day empagliflozin or placebo for 6 months.
- Primary outcome: 6-month change in LVMi to BSA from baseline, per cardiac MRI.
- Funding: Boehringer Ingelheim grant to authors.
- Baseline LVMi: 59.3 g/m2 empagliflozin vs 62.2 g/m2 placebo.
- LVMi change from baseline to 6 months:
- −2.6 g/m2 with empagliflozin vs
- −0.01 g/m2 with placebo;
- Adjusted between-group difference: −3.4 (−5.9 to −0.8) g/m2 (P=.01).
- Empagliflozin exposure was associated with mean BP reductions of 7.9 mmHg systolic and 3.1 mmHg diastolic vs no change in placebo group, for differences of:
- −6.8 mmHg (P=.003) systolic and
- −3.2 mmHg (P=.016) diastolic.
- Mean baseline hematocrit:
- 42.6% empagliflozin vs 41.3% placebo;
- 6-month increases of 2.4% and 2.8%, respectively;
- Adjusted difference, 2.3% (P=.0003).
- Mostly male participants.
- People with kidney disease, heart failure excluded.
- Small sample size.
- Brief follow-up.